Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
Main Authors: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
Frontiers Media S.A.
2021-10-01
|
Colecção: | Frontiers in Chemistry |
Assuntos: | |
Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
Registos relacionados
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
Por: Ridwan Abiodun Salaam, et al.
Publicado em: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
Por: Madhura Punekar, et al.
Publicado em: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
Por: Eswar Shankar, et al.
Publicado em: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
Por: Qihui Wu, et al.
Publicado em: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
Por: Rafeh Oualha, et al.
Publicado em: (2024-09-01)